Bank of America Forecasts Strong Price Appreciation for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by equities researchers at Bank of America from $263.00 to $275.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Bank of America‘s target price suggests a potential upside of 45.53% from the stock’s previous close.

A number of other research firms have also weighed in on JAZZ. Truist Financial upped their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating and set a $225.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. UBS Group reissued a “neutral” rating and set a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Finally, Needham & Company LLC lifted their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $213.85.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $188.97 on Wednesday. The company has a market capitalization of $11.63 billion, a price-to-earnings ratio of -31.65, a PEG ratio of 1.06 and a beta of 0.26. The company has a current ratio of 1.86, a quick ratio of 1.44 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $198.00. The business’s fifty day simple moving average is $169.18 and its 200-day simple moving average is $150.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the firm earned $6.51 earnings per share. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. On average, equities research analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 4,660 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the transaction, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at $1,200,454.40. This represents a 39.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after buying an additional 298,815 shares during the period. Capital World Investors boosted its holdings in shares of Jazz Pharmaceuticals by 4.4% in the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after acquiring an additional 111,735 shares during the last quarter. LSV Asset Management increased its stake in shares of Jazz Pharmaceuticals by 3.6% in the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after acquiring an additional 87,576 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat: Jazz reported Q4 revenue of ~$1.20B and EPS of $6.64, topping consensus and showing year-over-year revenue growth driven by neuroscience and oncology products. JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
• Positive Sentiment: Strong oxybate/Xywav growth is a core driver of the beat and underpins management’s optimism for 2026. Jazz Pharmaceuticals beats estimates on strong Xywav growth
• Positive Sentiment: 2026 revenue outlook raised: management projects $4.25B–$4.50B for 2026 while highlighting progress on rare-disease and oncology launches — a bullish forward signal. Jazz projects 4.25B–4.50B 2026 revenue
• Positive Sentiment: Multiple analyst price-target upgrades and bullish ratings after the print (Bank of America, Wells Fargo, Morgan Stanley, RBC) lift forward sentiment and imply substantial upside from current levels. Analyst price target raises TickerReport: BofA raise
• Neutral Sentiment: Detailed context available in the earnings call transcript and investor presentation for pipeline, launch timing and margin assumptions. Investors may want to review these for items that affect long-term modeling. Earnings Call Transcript Earnings Presentation
• Negative Sentiment: Near-term pullback/volatility drivers: the stock ran up into the print (near its 52‑week high), trading volume is elevated, and some investors are likely taking profits despite the beat — a plausible reason for the intraday decline.
• Negative Sentiment: Structural/valuation considerations: Jazz still has leverage on the balance sheet and reported a negative net margin in the background data; some investors may be cautious on margins and cash flow conversion as the company invests in launches. (See earnings coverage for metrics.) Earnings Call Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.